3Sbio Overview
- Founded
-
1993
- Status
-
Public
- Employees
-
5,160
- Stock Symbol
-
01530
- Investments
-
15
- Share Price
-
$1.15
- (As of Friday Closing)
3Sbio General Information
Description
3SBio Inc, or 3SBio, is one of the largest and most established biotech drugmakers in China. In 2021, it reported revenue of CNY 6.3 billion. Approximately 90% of its revenue is derived from four core drugs: TPIAO (rhTPO), Yisaipu (biosimilar of etanercept, a TNF-alpha inhibitor), rhEPO, and Mandi (minoxidil). With the exception of minoxidil, an over-the-counter drug, the others are all older generation biologics. Most of the pipeline candidates are "me-too" drugs and in general are still at an early stage.
Contact Information
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Stock Exchange
HKG
Primary Office
- 1st 3, 10th Road
- Economic and Technological Development Zone
- Shenyang, Liaoning
- China
+86 024 0000 0000
3Sbio Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.15 | $1.14 | $0.60 - $1.16 | $2.78B | 2.44B | 16.1M | $0.11 |
3Sbio Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 2,061,814 | 2,162,132 | 2,418,550 | 3,560,269 |
| Revenue | 985,293 | 988,374 | 808,793 | 769,663 |
| EBITDA | 348,297 | 335,390 | 193,473 | 232,014 |
| Net Income | 264,168 | 255,727 | 120,978 | 140,922 |
| Total Assets | 3,062,056 | 3,014,163 | 2,705,860 | 2,116,583 |
| Total Debt | 573,418 | 412,431 | 446,041 | 401,816 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
3Sbio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
3Sbio Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
3SBio Inc, or 3SBio, is one of the largest and most established biotech drugmakers in China. In 2021, it reported revenu
Pharmaceuticals
Shenyang, China
5,160
As of 2022
00000
00000000
00000
0000 0
et, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et d
000000000000000
Petah Tikva, Israel
00000
As of 0000
00000
00000000000
00000
000000
tur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna
0000 000000000
Suzhou, China
0000
As of 0000
00.000
000000000
00.000
Add Comparison
3Sbio Competitors (2)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Teva Pharmaceutical Industries | Corporate Backed or Acquired | Petah Tikva, Israel | 00000 | 00000 | 00000000000 | 00000 |
| 00000000 000000000 | Formerly PE-Backed | Suzhou, China | 0000 | 00.000 | 000000000 | 00.000 |
3Sbio Executive Team (6)
3Sbio Board Members (2)
| Name | Representing | Role | Since |
|---|---|---|---|
| 0000 000 00.0 | 3Sbio | Chief Executive Officer & Chairman | 000 0000 |
| 00 0000 | 3Sbio | Board Member | 000 0000 |
3Sbio Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
3Sbio Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
3Sbio Investments & Acquisitions (15)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000 00000 | 21-Oct-2019 | 00000 0000 | 0000 | Drug Discovery | 00000000 |
| 0000000 00000 | 12-Feb-2019 | 00000 0000 | 0000 | Drug Discovery | 00000000 |
| 000000 000000 | 02-May-2018 | 00000 0000 | 0000 | Drug Discovery | 0000 000 |
| 000000 000000 | 01-Dec-2017 | 00 0000000 | 000.00 | Biotechnology | 0000 000 |
| Therapure Biopharma (Contract Development & Manufacturing Assets) | 03-Sep-2017 | Merger/Acquisition | 00000 | Biotechnology | 0000 000 |
3Sbio Subsidiaries (2)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Sciprogen Bio-pharmaceutical | Other Pharmaceuticals and Biotechnology | Shenzhen, China | 1999 |
| 000000 00000000000 | Drug Delivery | Villa Guardia, Italy | 0000 |
3Sbio ESG
Risk Overview
Risk Rating
Updated March, 11, 2022
27.12 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,613
Rank
00.0
Percentile
Pharmaceuticals
Industry
00 of 1,004
Rank
00.00
Percentile
Biotechnology
Subindustry
00 of 462
Rank
00.00
Percentile
3Sbio Exits (2)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 000000000 000000 | 11-Feb-2010 | 000000000 | 000 | Completed |
|